



1006 Rec'd PCT/PTO 21 OCT 2005

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 03-004-F)

In the Application of:

Singh, et al.

Serial No.: 10/534,919

Filing Date: May 10, 2005

For: Rhodanine Derivatives And Pharmaceutical
Compositions Containing Them

Examiner: TBD

Group Art Unit: TBD

Confirmation No.: TBD

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) International Search Report;
- b) Information Disclosure Statement;
- c) PTO Form 1449 and 20 references cited therein; and
- d) return receipt postcard.

2. With respect to fees:

- a) A fee is not required at this time.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on October 19, 2005.

Date: October 19, 2005

Respectfully submitted,

Michael S. Greenfield
Registration No. 37,142

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 03-004-F)**

In the Application of:)	
)	
Singh, et al.)	
)	Examiner: TBD
Serial No.: 10/534,919)	
)	Group Art Unit: TBD
Filing Date: May 10, 2005)	
)	Confirmation No.: TBD
For: Rhodanine Derivatives And Pharmaceutical)	
Compositions Containing Them)	

INFORMATION DISCLOSURE STATEMENT

**Honorable Commissioner of Patents and Trademarks
P.O. Box 1450
Alexandria, Virginia 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449. For Information Disclosure Statements submitted after receipt of a foreign Search Report, a copy of such Search Report is attached.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 19, 2005.

Date: October 19, 2005


Michael S. Greenfield

U. S. PATENTS

1. Druzgala, et al., U.S. Publication No. US 2003/027798 A1, issued February 6, 2003.
2. Kawamatsu et al., U.S. Patent No. 4,376,777 A, issued March 15, 1983.

FOREIGN PATENT DOCUMENTS

3. WO Patent No. WO 01/77091 A, published 18 October 2001.
4. WO Patent No. WO 00/10573 A, published 2 March 2000.
5. WO Patent No. WO 01/81328 A, published 1 November 2001.
6. Great Britian Patent No. GB 2386892 A, published 1 October 2003.
7. Great Britian Patent No. GB 2387172 A, published 8 October 2003.
8. French Patent No. 2858324 A, published 4 February 2005.
9. WO Patent No. WO 04/024061 A, published 25 March 2004.

OTHER DOCUMENTS

10. Sohda, T. et al., "Antiulcer activity of 5-benzylthiazolidine-2,4-dione derivatives", Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, vol. 31, no. 2, February 1983, pages 560-569, XP002193484, ISSN: 0009-2363; examples 19, 35; table II example 40; table III.
11. Giles, R.G. et al., "Regiospecific Reduction of 5-Benzylidene-2, 4-thiazolidinediones and 4-Oxo-2-thiazolidinethiones using Lithium Borohydride in Pyridine and Tetrahydrofuran" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 56, no. 26, June 2000, pages 4531-4537, XP004202146, ISSN: 0040-4020, examples a,b,c,f,l; table 1.
12. Sutihnen, Jussi et al., "Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy", American Journal of Physiology, 286(6, PT. 1), E941-E949 CODEN: AJPHAP; ISSN: page E941, column 1.
13. Obushak, N.D. et al., "Synthesis of heterocycles based on products of anionarylation of unstuared compounds. II. Method of prepration of 2,5-disubstituted 4-thiazolidinones", Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii), 34(2), 239-244 Coden: RJOCEQ; ISSN: 1070-4280, 1998, XP008047401, examples XIa, b, c, d, f, g; table 2.
14. Kassab, Nazmi A. E. L., et al., "Reactions with 5-Substituted 2-thiazolidine-4-thiones. IV" Journal Fuer Praktische Chemie (Leipzig), 316(2), 209-14 Coden: JPCEAP; ISSN: 0021-8383, 1974, XP008047365 page 14; examples 6a, 6d.
15. Sing W. T. et al., "Arylalkylidene Rhodanine with Bulky and Hydrophobic Functional Gorup as Selective HCV NS3 Protease Inhibitor", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 11, no. 2, January 2001, pages 91-94, XP004314823, ISSN: 0960-894X, examples 2a, 2b, 2f-2h; table 1.
16. Awasthi, L.P. et al., "Antimicrobial activity of 3-methyl-5-furfurylidene-2-thioxo-4-thiazolidones" Folia Microbiologica (Prague, Czech Republic), 28(1), 41-5 CODEN: Fomiaz; ISSN: 0015-5632, 1983, XP008046916, page 41, page 42, paragraph 4, table 1.
17. Krutosikova, A. et al., "Furan derivatives XXIV. Synthesis of substituted 5-(5-phenjyl-2-


furfurylidene)rhodanines" Sbornik Prac Chemické Fakulty Svst, Volume Date 1969-1970 55-8
CODEN: SCFSAL: ISSN: 0520-7339, 1971, XP008046923, page 56; table 1.

18. Hardy, R.W. et al., "Hepatitis C virus RNA Synthesis in a cell-free system isolated from replicon-containing hepatoma cells", Journal of Virology, The American Society for Microbiology, US, vol. 77, no. 3, February 2003, pages 2029;2037, XP008046926, ISSN: 0022-538X, figure 7, page 2029, column 1 – column 2.
19. Chapman R. L. et al., "Small molecule modulators of HIV ref/rev response element interaction identified by random screening", Antiviral Research, Elsevier Science BV., Amsterdam, NL, vol. 54, no. 3, 2002, pages 149-162, XP008046900, ISSN: 0166-3542, figure 2; example 2, table 2, table 1
20. Spiegel P C, et al., "Disruption of Protein-Membrane Binding and Identification of Small-Molecule Inhibitors of Coagulation Factor VIII", Chemistry and Biology, Current Biology, London GB, vol. 11, no. 10, October 2004, pages 1413-1422, XP004601875, ISSN: 1074-5521; figure 3; examples 3,4.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: October 19, 2005

By:


Michael S. Greenfield
Reg. No. 37142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-004-F	Serial No. 10/534,919
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Rajinder Singh et al.	
		Filing Date: May 10, 2005	Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	2003/027798 A1	2/6/2003	Druzgala et al.			
	2.	4,376,777 A	3/15/1983	Kawamatsu et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	3.	WO 01/77091 A	18 October 2001	WO				
	4.	WO 00/10573 A	2 March 2000	WO				
	5.	WO 01/81328 A	1 November 2001	WO				
	6.	GB 2386892 A	1 October 2003	GB				
	7.	GB 2387172 A	8 October 2003	GB				
	8.	FR 2858324 A	4 February 2005	FR				
	9.	WO 2004/024061 A	25 March 2004	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

		10.	Sohda, T. et al., "Antiulcer activity of 5-benzylthiazolidine-2,4-dione derivatives", Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, JP, vol. 31, no. 2, February 1983, pages 560-569, XP002193484, ISSN: 0009-2363; examples 19, 35; table II example 40; table III.
		11.	Giles, R.G. et al., "Regiospecific Reduction of 5-Benzylidene-2, 4-thiazolidinediones and 4-Oxo-2-

			thiazolidinethiones using Lithium Borohydride in Pyridine and Tetrahydrofuran" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 56, no. 26, June 2000, pages 4531-4537, XP004202146, ISSN: 0040-4020, examples a,b,c,f,l; table 1.
		12.	Sutihnen, Jussi et al., "Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy", American Journal of Physiology, 286(6, PT. 1), E941-E949 CODEN: AJPHAP; ISSN: page E941, column 1.
		13.	Obushak, N.D. et al., "Synthesis of heterocycles based on products of anionarylation of unstuared compounds. II. Method of prepration of 2,5-disubstituted 4-thiazolidinones", Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii), 34(2), 239-244 Coden: RJOCEQ; ISSN: 1070-4280, 1998, XP008047401, examples XIa, b, c, d, f, g; table 2.
		14.	Kassab, Nazmi A. E. L., et al., "Reactions with 5-Substituted 2-thiazolidine-4-thiones. IV" Journal Fuer Praktische Chemie (Leipzig), 316(2), 209-14 Coden: JPCEAP; ISSN: 0021-8383, 1974, XP008047365 page 14; examples 6a, 6d.
		15.	Sing W. T. et al., "Arylalkylidene Rhodanine with Bulky and Hydrophobic Functional Gorup as Selective HCV NS3 Protease Inhibitor", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 11, no. 2, January 2001, pages 91-94, XP004314823, ISSN: 0960-894X, examples 2a, 2b, 2f-2h; table 1.
		16.	Awasthi, L.P. et al., "Antimicrobial activity of 3-methyl-5-furfurylidene-2-thioxo-4-thiazolidones" Folia Microbiologica (Prague, Czech Republic), 28(1), 41-5 CODEN; Fomiaz; ISSN: 0015-5632, 1983, XP008046916, page 41, page 42, paragraph 4, table 1.
		17.	Krutosikova, A. et al., "Furan derivatives XXIV. Synthesis of substituted 5-(5-phenjyl-2-furfurylidene)rhodanines"Sbornik Prac Chemickej Fakulty Svst, Volume Date 1969-1970 55-8 CODEN: SCFSAL; ISSN: 0520-7339, 1971, XP008046923, page 56; table 1.
		18.	Hardy, R.W. et al., "Hepatitis C virus RNA Synthesis in a cell-free system isolated from replicon-containing hepatoma cells", Journal of Virology, The American Society for Microbiology, US, vol. 77, no. 3, February 2003, pages 2029;2037, XP008046926, ISSN: 0022-538X, figure 7, page 2029, column 1 – column 2.
		19.	Chapman R. L. et al., "Small molecule modulators of HIV ref/rev response element interaction identified by random screening", Antiviral Research, Elsevier Science BV., Amstgerdam, NL, vol. 54, no. 3, 2002, pages 149-162, XP008046900, ISSN: 0166-3542, figure 2; example 2, table 2, table 1
		20.	Spiegel P C, et al., "Disruption of Protein-Memrain Binding and Identification of Small-Molecule Inhibitors of Coagulation Factor VIII", Chemistry and Biology, Current Biology, London GB, vol. 11, no. 10, October 2004, pagews 1413-1422, XP004601875, ISSN: 1074-5521; figure 3; examples 3,4.
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.